StemCells, Inc. Announces Webcast to Discuss Second Quarter Financial Results and Business Update
July 25 2011 - 9:00AM
StemCells, Inc. (Nasdaq:STEMD), a leading stem cell company
developing and commercializing novel cell-based therapeutics and
tools for use in stem cell-based research and drug discovery,
announced today that it will release financial results for the
second quarter ended June 30, 2011 after the market closes on
Thursday, July 28. In connection with this announcement, StemCells
will host a conference call and webcast to discuss its results and
an update on its business at 1:30 p.m. Pacific Time (4:30 p.m.
Eastern Time) the same day.
Interested parties are invited to listen to the call over the
Internet by accessing the Investors section of the Company's
website at www.stemcellsinc.com. Webcast participants should allot
extra time before the webcast begins to register and, if necessary,
download and install audio software.
Event: |
Q2 2011 Financial Results Conference Call /
Webcast |
Date: |
July 28, 2011 |
Time: |
1:30 PM PT (4:30 PM ET) |
Live
webcast: http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-irhome
An archived version of the webcast will also be available for
replay on the Company's website beginning approximately two hours
following the conclusion of the live call and continuing for a
period of 30 days.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and
commercialization of cell-based therapeutics and tools for use in
stem cell-based research and drug discovery. The Company's lead
therapeutic product candidate, HuCNS-SC® cells (purified human
neural stem cells), is currently in development as a potential
treatment for a broad range of central nervous system
disorders. Clinical trials are currently underway in spinal
cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children. In addition, the Company
plans to file an IND by year-end 2011 to initiate a clinical trial
of HuCNS-SC cells in age-related macular degeneration, and is also
pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's
disease and stroke. StemCells also markets stem cell research
products, including media and reagents, under the SC Proven® brand,
and is developing stem cell-based assay platforms for use in
pharmaceutical research, drug discovery and drug development.
Further information about StemCells is available at
http://www.stemcellsinc.com.
The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014
Apart from statements of historical fact, the text of this press
release constitutes forward-looking statements within the meaning
of the U.S. securities laws, and is subject to the safe harbors
created therein. These statements include, but are not limited
to, statements regarding the clinical development of its HuCNS-SC
cells; the timing and prospects associated with filing an IND to
initiate a clinical trial in age-related macular degeneration; the
Company's ability to commercialize drug discovery and drug
development tools; and the future business operations of the
Company. These forward-looking statements speak only as of the date
of this news release. The Company does not undertake to update any
of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks and
uncertainties to which the Company is subject, including those
described under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2010 and in its
subsequent reports on Form 8-K.
CONTACT: Rodney Young
Chief Financial Officer
(510) 456-4128
Stemcells, Inc. (MM) (NASDAQ:STEMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Stemcells, Inc. (MM) (NASDAQ:STEMD)
Historical Stock Chart
From Jul 2023 to Jul 2024